QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touchService navigator
QPS NEUROPHARMACOLOGY

Preclinical CRO for

Get in touch

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

QPS Neuropharmacology is a preclinical full-service contract research organization (CRO) focusing on CNS diseases, Orphan diseases and mental disorders.

The availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes QPS the first choice for most needs in CNS drug development.

Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Lewy Body Dementia (LBD) and other neurodegenerative diseases.

Why choose us?

Customer satisfaction is our absolute priority

Your timeline is our timeline

f

Every study is custom-built

p

Scientific input to study design and data interpretation

Extensive experience with virtually all drug targets and treatment types

0

Wide range of validated models and techniques for comprehensive compound tests from a single source

AAALAC certification ensures highest quality standards

QPS Austria AAALAC accrediation Logo

QPS NEURO NEWS

QPS Austria now offers the Tau transgenic PS19 mouse for your research!

 QPS Austria now offers the Tau transgenic PS19 mouse for your research!

QPS Austria now licensed the PS19 transgenic mouse from the University of Pennsylvania, USA (JAX 008169; Yoshiyama et al., 2007). The mouse expresses the T34 isoform and 4 microtubule binding repeats (1N4R) of the tau protein with P301S mutation under the regulatory control of the murine prion promoter (Prnp). PS19 mice are a popular model to study tau aggregation, tauopathy and other symptoms of Alzheimer`s disease.

 

 

Animals present the following phenotype:

  • Neuronal accumulation of phosphorylated tau and paired helical filaments (PHF) in different brain regions at 6 months (Yoshiyama et al., 2007)
  • Cerebral atrophy and neuron loss at 12 months (Yoshiyama et al., 2007)
  • Neuroinflammation observed as activated microglia and astrocytosis at 6 months and older (Yoshiyama et al., 2007; Lopez-Gonzalez et al., 2015)
  • Muscle weakness and neurogenic muscular atrophy at 3 months (Yoshiyama et al., 2007)
  • Reduced anxiety at 9 months (Briggs et al., 2017)
  • Learning and memory deficits at 9 months (Briggs et al., 2017)
  • Reduced survival (Yoshiyama et al., 2007)

Results from published efficacy studies show that many of these symptoms are partly reversible by different compounds:

  • Survival, nueroinflammation, tau phosphorylation (Yoshiyama et al., 2007)
  • Axonal dystrophy, learning an memory (Brunden et al., 2010)
  • Brain atrophy, survival, nest building (DeVos et al., 2017)

The phenotype described above, relevant for AD and other neurodegenerative disorder, makes the PS19 mouse a perfect model for your drug testing.

Watch recording!

Webinar “Predictive Disease Models for CNS Drug Development“

 

In November 2018, Birgit Hutter-Paier, PhD, the Director of Neuropharmacology at QPS Austria presented this webinar about validated transgenic and non-transgenic in vitro and in vivo models covering most targets of AD, PD, HD and other neurodegenerative diseases.

 

Birgit Hutter-Paier

  You will learn:

  • When to use animal models in your drug discovery program
  • How to choose the most appropriate animal model for your therapeutic or mechanism of action
  • How to design the most efficient “first-pass” proof-of-concept study
  • Best practices for submitting compounds and sample requirements for a successful study

 

Brought to you by ADDF ACCESS, a program of the ADDF and Science Exchange, as part of their commitment to connect researchers developing CNS drugs with technologies that can help accelerate breakthrough discoveries.

Format: 30 minutes with 10 minutes Q&A

Watch recording!

In Vitro Services

QPS Austria’s Neuropharmacology Department provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.

In Vivo Services

We have more than 15 years experience in generating, characterizing and maintaining transgenic disease models and using them for drug testing projects. Several customized behavioral tests, including motor, cognitive, and emotional assays, are offered to phenotype mouse and rat models and to evaluate effects of compounds in different in vivo models.

Ex Vivo Services

Our ex vivo services cover a full range of histological services, a biobank composed of various specimen derived from our in-house in vivo and in vitro models, and numerous well established tests for biomarkers. We are happy to test new protocols and establish new markers to meet your specific needs.